Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis

—Preparations for the Nebokitug PSC Phase 3 Clinical Trial Advance as Discussions with Potential Strategic Partners Continue— —Achieves FDA Alignment on CMC and Non-Clinical Toxicology Regulatory Path for Nebokitug in PSC— FDA fully approved therapy; the risk that the full data set from the nebokitug study or data generated in further clinical trials of nebokitug may not be consistent with the results of the nebokitug Phase 2 PSC trial; failure to obtain, or delays in obtaining, regulatory approvals for neb ...